Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity.
advanced endometrial cancer
immunotherapy
lenvatinib
lung toxicity
pembrolizumab
targeted therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
03
2023
accepted:
07
06
2023
medline:
26
7
2023
pubmed:
26
7
2023
entrez:
26
7
2023
Statut:
epublish
Résumé
The optimal strategy for the treatment of recurrent and/or advanced endometrial cancer is still undefined. Recently, despite the lack of any predictive biomarker, the combination of pembrolizumab with lenvatinib has improved survival outcomes. We here report the long-term management of lung toxicity in a patient with endometrial cancer, and we critically review the current therapeutic options for this disease. A patient with heavily pretreated endometrial cancer took pembrolizumab plus lenvatinib for 1 year, achieving a persistent partial response with a time to treatment failure of 18 months, despite relevant lung toxicity that did not affect the remarkable overall clinical benefit. A systematic review of this combination underlines the efficacy outcome despite toxicity. Interestingly, the literature review on lung toxicity suggested the role of anti-angiogenetic agents in the pathogenesis of lung cavitation, probably related to direct treatment activity, and disclosed a potential radiological sign predictive of the activity of anti-angiogenetic agents. We underline the efficacy of pembrolizumab plus lenvatinib in the current treatment landscape of endometrial cancer, underscoring the relevance of a correct management of toxicity.
Sections du résumé
Background
UNASSIGNED
The optimal strategy for the treatment of recurrent and/or advanced endometrial cancer is still undefined. Recently, despite the lack of any predictive biomarker, the combination of pembrolizumab with lenvatinib has improved survival outcomes. We here report the long-term management of lung toxicity in a patient with endometrial cancer, and we critically review the current therapeutic options for this disease.
Results
UNASSIGNED
A patient with heavily pretreated endometrial cancer took pembrolizumab plus lenvatinib for 1 year, achieving a persistent partial response with a time to treatment failure of 18 months, despite relevant lung toxicity that did not affect the remarkable overall clinical benefit. A systematic review of this combination underlines the efficacy outcome despite toxicity. Interestingly, the literature review on lung toxicity suggested the role of anti-angiogenetic agents in the pathogenesis of lung cavitation, probably related to direct treatment activity, and disclosed a potential radiological sign predictive of the activity of anti-angiogenetic agents.
Conclusion
UNASSIGNED
We underline the efficacy of pembrolizumab plus lenvatinib in the current treatment landscape of endometrial cancer, underscoring the relevance of a correct management of toxicity.
Identifiants
pubmed: 37492471
doi: 10.3389/fonc.2023.1145986
pmc: PMC10363977
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1145986Informations de copyright
Copyright © 2023 Staropoli, Salvino, Falcone, Farenza, Costa, Rossini, Manti, Crispino, Riillo, Ciliberto, Arbitrio, Tassone and Tagliaferri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Gynecol Cancer. 2022 Jan;32(1):93-100
pubmed: 34799418
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Cancers (Basel). 2020 Nov 10;12(11):
pubmed: 33182707
Hum Pathol. 2006 Nov;37(11):1465-72
pubmed: 16949921
J Cancer Res Clin Oncol. 2018 Jul;144(7):1339-1346
pubmed: 29774414
J Clin Oncol. 2017 Dec 20;35(36):4035-4041
pubmed: 29095678
Methods Mol Biol. 2022;2401:1-12
pubmed: 34902118
Int J Gynecol Cancer. 2017 Mar;27(3):452-458
pubmed: 28187088
Radiol Imaging Cancer. 2022 Mar;4(2):e220012
pubmed: 35302394
BMC Cancer. 2013 Apr 26;13:207
pubmed: 23617826
N Engl J Med. 2020 Nov 19;383(21):2053-2064
pubmed: 33207095
Lancet Oncol. 2012 Aug;13(8):e353-61
pubmed: 22846840
Lung. 2018 Feb;196(1):1-10
pubmed: 29143119
Rev Mal Respir. 2022 Sep;39(7):626-632
pubmed: 35906150
Clin J Gastroenterol. 2021 Feb;14(1):288-292
pubmed: 33108567
Intern Med. 2005 Aug;44(8):862-4
pubmed: 16157988
Thorac Cancer. 2020 Sep;11(9):2727-2730
pubmed: 32691523
Crit Rev Oncol Hematol. 2021 Jul;163:103366
pubmed: 34051303
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Front Immunol. 2021 Jun 02;12:689132
pubmed: 34149730
PLoS One. 2022 Mar 16;17(3):e0264138
pubmed: 35294956
Curr Treat Options Oncol. 2022 Dec;23(12):1818-1828
pubmed: 36417148
Gynecol Oncol. 2022 Jan;164(1):146-153
pubmed: 34802721
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Gynecol Oncol. 2021 Jun;161(3):720-726
pubmed: 33894982
Clin Transl Sci. 2021 Jan;14(1):113-119
pubmed: 33089968
J Oncol Pharm Pract. 2023 May 25;:10781552231178461
pubmed: 37231712
J Clin Oncol. 2020 Sep 10;38(26):2981-2992
pubmed: 32167863
J Clin Oncol. 2023 Feb 10;41(5):974-979
pubmed: 36608305
Expert Opin Investig Drugs. 2019 Feb;28(2):131-142
pubmed: 30574817
Front Pharmacol. 2023 Mar 03;13:1063178
pubmed: 36937206
Cancer Res. 1997 Mar 1;57(5):808-11
pubmed: 9041175
Gland Surg. 2022 Jun;11(6):963-969
pubmed: 35800737
Adv Pharm Bull. 2023 Jan;13(1):88-95
pubmed: 36721805
Methods Mol Biol. 2022;2401:239-248
pubmed: 34902132
Hepatology. 2021 Nov;74(5):2544-2560
pubmed: 34036623
Expert Rev Anticancer Ther. 2018 Sep;18(9):873-885
pubmed: 29972650
South Med J. 2020 Nov;113(11):600-605
pubmed: 33140115
Jpn J Clin Oncol. 2011 Feb;41(2):269-71
pubmed: 21030401
J Clin Oncol. 2019 Jun 10;37(17):1470-1478
pubmed: 30943124
Gynecol Oncol. 2023 Feb;169:27-33
pubmed: 36493574
Gynecol Oncol. 2018 Sep;150(3):569-580
pubmed: 29843906
High Throughput. 2018 Dec 18;7(4):
pubmed: 30567415
Lung India. 2022 Mar-Apr;39(2):158-168
pubmed: 35259799
J Clin Oncol. 2023 Jun 1;41(16):2904-2910
pubmed: 37058687
Gynecol Oncol. 2022 Mar;164(3):558-565
pubmed: 34998597
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Cochrane Database Syst Rev. 2019 Oct 07;10:CD012160
pubmed: 31588998
Ginekol Pol. 2021;92(1):16-23
pubmed: 33448001
Nat Genet. 2009 Jan;41(1):112-7
pubmed: 19098912
JAMA Oncol. 2020 Nov 01;6(11):1766-1772
pubmed: 33001143
Gynecol Oncol. 2009 Aug;114(2):242-5
pubmed: 19447480
Int J Gynecol Cancer. 2022 Apr 4;32(4):579
pubmed: 35190462
Cancers (Basel). 2022 Aug 29;14(17):
pubmed: 36077713
Ann Oncol. 2007 Mar;18(3):409-20
pubmed: 17150999